4SC Overview

  • Year Founded
  • 1997

Year Founded

  • Status
  • Public

  • Employees
  • 11

Employees

  • Stock Symbol
  • VSC

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $0.12
  • (As of Tuesday Closing)

4SC General Information

Description

4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. Its pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development resminostat and Domatinostat. The geographic area of the company is Germany, the EU, and Other countries, and the majority of the revenue comes from Other Countries.

Contact Information

Website
www.4sc.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Fraunhoferstrasse 22
  • 82152 Planegg-Martinsried
  • Germany
+49 089
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
FRA
Vertical(s)
Corporate Office
  • Fraunhoferstrasse 22
  • 82152 Planegg-Martinsried
  • Germany
+49 089

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

4SC Stock Performance

As of 16-Dec-2025, 4SC’s stock price is $0.12.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.12 $0.15 $0.10 - $6.56 13.2M 6.42K -$0.73

4SC Financials Summary

As of 31-Dec-2025, 4SC has a trailing 12-month revenue of $2.92M.

In Thousands,
USD
TTM 31-Dec-2025 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV (4,840) (4,840)
Revenue 2,918 2,918 364 329
EBITDA (3,428) (3,428) (8,355) (8,494)
Net Income (3,922) (3,922) (9,018) (8,913)
Total Assets 9,187 9,187 9,222 10,394
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

4SC Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore 4SC‘s full profile, request access.

Request a free trial

4SC Patents

4SC Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2021064188-A1 Combination comprising hdac inhibitor, ctla-4 inhibitor and a pd-1 inhibitor or pd-l1 inhibitor for cancer treatment Inactive 02-Oct-2019
AU-2019254578-A1 Combination comprising hdac inhibitor, lag-3 inhibitor and a pd-1 inhibitor or pd-l1 inhibitor for cancer treatment Inactive 17-Apr-2018
CA-3097087-A1 Combination comprising hdac inhibitor, lag-3 inhibitor and a pd-1 inhibitor or pd-l1 inhibitor for cancer treatment Inactive 17-Apr-2018
EP-3781159-A1 Combination comprising hdac inhibitor, lag-3 inhibitor and a pd-1 inhibitor or pd-l1 inhibitor for cancer treatment Inactive 17-Apr-2018
US-20230201161-A1 Combination comprising hdac inhibitor, lag-3 inhibitor and a pd-1 inhibitor or pd-l1 inhibitor for cancer treatment Inactive 17-Apr-2018 A61K31/40
To view 4SC’s complete patent history, request access »

4SC Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

4SC Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore 4SC‘s full profile, request access.

Request a free trial

4SC Investments (3)

4SC’s most recent deal was a Seed Round with Panoptes Pharma for . The deal was made on 02-Nov-2015.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Panoptes Pharma 02-Nov-2015 Seed Round Drug Discovery
8 Oncology Projects 31-Jul-2008 Corporate Asset Purchase Buildings and Property
Nexigen 26-May-2008 Corporate Drug Discovery
To view 4SC’s complete investments history, request access »

4SC ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view 4SC’s complete esg history, request access »

4SC Exits (2)

4SC’s most recent exit was on 02-Nov-2015 from Panoptes Pharma. The exit was categorized as with 4 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Panoptes Pharma 02-Nov-2015 Completed
  • 4 buyers
Nexigen 26-May-2008 Corporate Completed
To view 4SC’s complete exits history, request access »

4SC Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
4SC Discovery Munich, Germany 1997

4SC FAQs

  • When was 4SC founded?

    4SC was founded in 1997.

  • Where is 4SC headquartered?

    4SC is headquartered in Planegg-Martinsried, Germany.

  • What is the size of 4SC?

    4SC has 11 total employees.

  • What industry is 4SC in?

    4SC’s primary industry is Drug Discovery.

  • Is 4SC a private or public company?

    4SC is a Public company.

  • What is 4SC’s stock symbol?

    The ticker symbol for 4SC is VSC.

  • What is the current stock price of 4SC?

    As of 16-Dec-2025 the stock price of 4SC is $0.12.

  • What is 4SC’s current revenue?

    The trailing twelve month revenue for 4SC is $2.92M.

  • What is 4SC’s annual earnings per share (EPS)?

    4SC’s EPS for 12 months was -$0.73.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process